Centaurus Financial Inc. Purchases Shares of 2,800 Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE)

Centaurus Financial Inc. purchased a new stake in shares of Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 2,800 shares of the biotechnology company’s stock, valued at approximately $119,000.

A number of other hedge funds have also bought and sold shares of the stock. Virtu Financial LLC acquired a new position in Cerevel Therapeutics during the 4th quarter valued at approximately $246,000. Perceptive Advisors LLC increased its stake in Cerevel Therapeutics by 8.7% during the 4th quarter. Perceptive Advisors LLC now owns 10,965,193 shares of the biotechnology company’s stock valued at $464,924,000 after purchasing an additional 876,808 shares in the last quarter. Governors Lane LP acquired a new position in Cerevel Therapeutics during the 4th quarter valued at approximately $15,451,000. Twin Securities Inc. acquired a new stake in shares of Cerevel Therapeutics in the fourth quarter worth $9,867,000. Finally, PenderFund Capital Management Ltd. acquired a new stake in shares of Cerevel Therapeutics in the fourth quarter worth $399,000. Institutional investors and hedge funds own 87.73% of the company’s stock.

Cerevel Therapeutics Stock Up 0.9 %

NASDAQ:CERE opened at $41.85 on Thursday. The firm has a market capitalization of $7.63 billion, a P/E ratio of -15.33 and a beta of 1.41. Cerevel Therapeutics Holdings, Inc. has a 1-year low of $19.59 and a 1-year high of $43.59. The company’s fifty day moving average price is $41.69 and its 200-day moving average price is $41.72. The company has a debt-to-equity ratio of 0.60, a current ratio of 10.22 and a quick ratio of 10.22.

Cerevel Therapeutics (NASDAQ:CERE) last released its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported ($0.73) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.12). As a group, equities research analysts anticipate that Cerevel Therapeutics Holdings, Inc. will post -2.63 EPS for the current year.

Insider Transactions at Cerevel Therapeutics

In other news, Director N Anthony Coles sold 50,000 shares of the stock in a transaction on Friday, May 10th. The shares were sold at an average price of $42.10, for a total value of $2,105,000.00. Following the sale, the director now owns 15,638 shares in the company, valued at $658,359.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 5.10% of the company’s stock.

About Cerevel Therapeutics

Cerevel Therapeutics Holdings, Inc, a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model.